FDA Rejects Merck’s Arcoxia
It isn’t surprising that the FDA rejected Merck’s NDA for Arcoxia, its follow on to Vioxx since an advisory committee already voted 20-1 against its approval. Forbes has an article on it.
FDA Rejects Merck’s Vioxx Successor - Forbes.com:
It is interesting to note though that Arrcoxia is on sale in 63 countries world-wide already. It be be interesting to see what effect if any it has on world-wide sales.
Technorati Tags: Arcoxia, Merck, Vioxx
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
